Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raisman, R
Right arrow Articles by Agid, Y
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raisman, R
Right arrow Articles by Agid, Y

NEUROLOGY 1986;36:556-560
© 1986 American Academy of Neurology

ARTICLES

Parkinson's disease: decreased density of 3H-imipramine and 3H- paroxetine binding sites in putamen

R Raisman, R Cash and Y Agid

The density of high-affinity 3H-imipramine and 3H-paroxetine binding sites (two serotonin-uptake blockers) was decreased in the putamen of parkinsonian patients. The correlation between serotonin levels and the number of 3H-imipramine and 3H-paroxetine binding sites suggests that they are located on serotoninergic nerve terminals and could be used to study serotoninergic innervation in the human brain. Since imipramine and paroxetine are powerful antidepressants, these results furthermore suggest that decreased serotoninergic transmission may be implicated in the pathophysiology of depression in Parkinson's disease.


This article has been cited by other articles:


Home page
 BrainHome page
S. J. Kish, J. Tong, O. Hornykiewicz, A. Rajput, L.-J. Chang, M. Guttman, and Y. Furukawa
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease
Brain, January 1, 2008; 131(1): 120 - 131.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
L. Kerenyi, G. A. Ricaurte, D. J. Schretlen, U. McCann, J. Varga, W. B. Mathews, H. T. Ravert, R. F. Dannals, J. Hilton, D. F. Wong, et al.
Positron Emission Tomography of Striatal Serotonin Transporters in Parkinson Disease
Arch Neurol, September 1, 2003; 60(9): 1223 - 1229.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. E. Kim, J. Y. Choi, Y. S. Choe, Y. Choi, and W. Y. Lee
Serotonin Transporters in the Midbrain of Parkinson's Disease Patients: A Study with 123I-{beta}-CIT SPECT
J. Nucl. Med., June 1, 2003; 44(6): 870 - 876.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Doder, E. A. Rabiner, N. Turjanski, A. J. Lees, and D. J. Brooks
Tremor in Parkinson's disease and serotonergic dysfunction: An 11C-WAY 100635 PET study
Neurology, February 25, 2003; 60(4): 601 - 605.
[Abstract] [Full Text] [PDF]

Home page
 PsychosomaticsHome page
L. Marsh
Neuropsychiatric Aspects of Parkinson's Disease
Psychosomatics, February 1, 2000; 41(1): 15 - 23.
[Abstract] [Full Text]

Home page
 Arch NeurolHome page
M. R. Pranzatelli
Serotonin and Human Myoclonus: Rationale for the Use of Serotonin Receptor Agonists and Antagonists
Arch Neurol, June 1, 1994; 51(6): 605 - 617.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
M. Sano, M. Stanley, A. Lawton, L. Cote, J. Williams, Y. Stern, K. Marder, and R. Mayeux
Tritiated Imipramine Binding: A Peripheral Marker for Serotonin in Parkinson's Disease
Arch Neurol, October 1, 1991; 48(10): 1052 - 1054.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by AAN Enterprises, Inc.